Measurement of Serum 1,25-dihydroxyvitamin D

This policy covers measurement of serum 1,25‑dihydroxyvitamin D for diagnosis and monitoring of specific disorders—including chronic kidney disease, hereditary phosphate‑losing disorders, oncogenic osteomalacia, pseudovitamin D‑ or vitamin D‑resistant rickets, granulomatous diseases (eg, sarcoidosis, some lymphomas), hyperparathyroidism—and selected high‑risk or vitamin D‑deficient populations. It specifies major limitations: 1,25(OH)2D is not useful for routine assessment of vitamin D status (25[OH]D is the preferred test), should not be used for screening average‑risk asymptomatic individuals, and is generally not covered in the absence of hypercalcemia or decreased kidney function; applicable state Medicaid and Medicare determinations take precedence.

"Monitoring in chronic kidney disease"

Sign up to see full coverage criteria, indications, and limitations.